3-(4-(1-(naphthalen-2-ylsulfonyl)piperidin-4-yl)butylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione | 1338213-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(4-(1-(naphthalen-2-ylsulfonyl)piperidin-4-yl)butylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
• 英文别名: 3-[4-(1-Naphthalen-2-ylsulfonylpiperidin-4-yl)butylamino]-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
• CAS: 1338213-20-9
• 化学式: C₂₈H₃₀N₄O₄S
• 分子量: 518.637
• InChiKey: LGBZLYJTKILCTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY<br/>[FR] DÉRIVÉS DE PYRIDINYLE COMPRENANT UN GROUPEMENT CYANOGUANIDINE OU ACIDE SQUARIQUE
  申请人：TOPOTARGET AS

  公开号：WO2011121055A1

  公开（公告）日：2011-10-06

  The present application discloses compounds of the formula (I) wherein X = opt.subst. pyrid-3-yl or pyrid-4-yl; Q = opt.subst. Ci-6 alkylene or a single bond; Y is formula (i) wherein D is = N-CN, or formula (ii) B = is opt.subst. C1-6 alkylene; A = (formula) Z = -J-V, wherein J = -C(=0)-, -C(=O)-O, -S(=O)2-, -P(=O)(OR4)-, -C(=O)-NR4- and -C(=S)-NR4-, and V = opt.subst. C1-12-alkyl, opt.subst. C3-12-cycloalkyl, -[CH2CH2O]1-10-( opt.subst. C1-6-alkyl), opt.subst. C1-12- alkenyl, opt.subst. aryl, opt.subst. heterocyclyl, or opt.subst. heteroaryl; q = 0-2, and r = 0- 2; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

  本申请公开了以下式(I)的化合物，其中X = opt.subst.吡啶-3-基或吡啶-4-基; Q = opt.subst. Ci-6烷基或单键; Y是式(i)，其中D = N-CN，或式(ii)中的B = opt.subst. C1-6烷基; A = (式) Z = -J-V，其中J = -C(=0)-，-C(=O)-O，-S(=O)2-，-P(=O)(OR4)-，-C(=O)-NR4-和-C(=S)-NR4-，V = opt.subst. C1-12-烷基，opt.subst. C3-12-环烷基，-[CH2CH2O]1-10-(opt.subst. C1-6-烷基)，opt.subst. C1-12-烯基，opt.subst. 芳基，opt.subst. 杂环烷基，或opt.subst. 杂环芳基; q = 0-2，r = 0-2; 及其药学上可接受的盐和前药。该申请还公开了该化合物用作治疗由烟酰胺磷酸核糖转移酶（NAMPRT）水平升高引起的疾病或病症的药物，例如炎症和组织修复紊乱; 皮肤病; 自身免疫疾病，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱症，与感染和某些病毒感染相关的炎症，包括获得性免疫缺陷综合症（AIDS），成人呼吸窘迫综合征，遗传性毛细血管扩张。